Molecular epidemiology and antimicrobial resistance phenotype of paediatric bloodstream

infections caused by Gram-negative bacteria in Oxfordshire, UK

Sam Lipworth[1,2], Karina-Doris Vihta[1,3], Tim Davies[1,2], Sarah Wright[2], Merline Tabirao[2], Kevin Chau[1],

Alison Vaughan[1], James Kavanagh[1], Leanne Barker[1], Sophie George[1], Shelley Segal[2], Stephane

Paulus[2], Lucinda Barrett[2], Sarah Oakley[2], Katie Jeffery[2], Lisa Butcher[2], Tim Peto[1,2,4,5], Derrick

Crook[1,2,4,5], Sarah Walker[1,4,5], Seilesh Kadambari[2,6]* and Nicole Stoesser[1,2]*

*Joint Senior Authors

[1]Nuffield Department of Medicine, University of Oxford, UK

[2]Oxford University Hospitals NHS Foundation Trust, Oxford, UK

[3]Department of Engineering, University of Oxford, UK

[4]NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial

Resistance at University of Oxford in partnership with Public Health England, Oxford, United

Kingdom

[5]NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

[6]Department of Paediatrics, University of Oxford, UK

Keywords: neonatal sepsis, paediatric bloodstream infections, whole genome sequencing,

antimicrobial resistance

Running Title: Sequencing of paediatric Gram-negative sepsis

Corresponding author: Dr S Lipworth, Samuel.lipworth@ndm.ox.ac.uk

Alternate corresponding author: Dr N Stoesser Nicole.stoesser@ndm.ox.ac.uk

Abstract:

Objectives: Gram-negative organisms are common causes of bloodstream infection (BSI) during the neonatal period and early childhood. Whilst several large studies have characterised these isolates in adults, equivalent data (particularly incorporating whole genome sequencing) is lacking in the paediatric population.

Methods: We performed an epidemiological and sequencing based analysis of Gram-negative bloodstream infections in children <18 years old between 2008 and 2018 in Oxfordshire, UK.

Results: 327 isolates (296 successfully sequenced) from 287 patients were included. The burden of infection was predominantly in neonates (124/327[38%]). Most infections were caused by *Escherichia coli (149/327[46%])/Klebsiella* spp. (69/327[21%]) and *Enterobacter hormaechei (34/327[10%])*. There was no evidence of an increasing incidence of *E. coli* BSIs (IRRy 0.96, 95%CI 0.90-1.30, p=0.30) and for *Klebsiella* spp. there was some evidence that the incidence decreased slightly (IRRy 0.91, 95%CI 0.83-1.00, p=0.06). Similarly the proportion of antimicrobial resistant (across all antimicrobial classes evaluated) isolates did not change over time, though we did identify some evidence of sub-breakpoint increases in gentamicin resistance IRRy 1.86, 95%CI 1.33-2.58, $p_{heterogeneity}$=0.002. The population structure of *E. coli* BSI isolates in neonates and children mirrors that in adults with a predominance of STs 131/95/73/69 and the same proportion of O-antigen serotypes covered by the ExPEC-4V vaccine. In most cases there was no evidence of transmission/point-source acquisition and whole genome sequencing was able to refute a previously suspected *Serratia marcescens* outbreak.

Conclusion: Our findings support continued use of current empirical treatment guidelines and suggest that O-antigen targeted vaccines may have a role in reducing the incidence of neonatal sepsis.

Introduction

Gram-negative bloodstream infections (GNBSI) are a common cause of significant morbidity and mortality globally in neonates and young children[1-4]. Their incidence has increased in both the UK and US over the past decade, particularly in very low birth-weight neonates (VLBW, defined as <1500g)[5,6]. Their association with antimicrobial resistance (AMR) has been highlighted by a recent study in the United States of 721 *E. coli* isolates (including 393 bloodstream infection [BSI]-associated isolates), which found high rates of non-susceptibility to commonly used empirical antibiotics including ampicillin (66.8%) and gentamicin (16.8%), as well as an extended beta-lactamase (ESBL) phenotype in 1 in 20 cases[7]. A recent study of 2,483 neonates with culture-confirmed sepsis in low and middle-income countries showed that *Klebsiella* spp. was the predominant pathogen causing multidrug-resistant neonatal sepsis[8]. In Greece, a retrospective observational study in 16 neonatal intensive care units (NICUs) revealed almost half (45%; 36/80) of *Klebsiella* spp. were resistant to either gentamicin or amikacin[9]. The ability of many Gram-negative bacilli (GNB) to readily acquire and exchange genetic material (particularly AMR genes [ARGs]) via mobile genetic elements means that the proliferation of drug-resistant strains remains a constant threat.

The molecular epidemiology of *E. coli* and *Klebsiella* spp. isolates causing invasive infection in adults has been characterised in large sequencing studies.[10,11] These have demonstrated the emergence of particular AMR-associated sequence types (e.g. *E. coli* ST131), the genetic homogeneity of isolates causing community and nosocomial onset infections suggesting a common reservoir, the potential for vaccines to play a role in reducing the incidence of these infections, and the emerging threat of the convergence of multidrug resistance and hypervirulence in *Klebsiella* spp. To our knowledge, no study to date has systematically evaluated the molecular epidemiology of *E. coli/Klebsiella* spp. and other common causes of GNBSI in a paediatric population; published studies focus predominantly on

evaluations of outbreaks caused by AMR-associated strains and/or on neonates (see above)[8,12,13]. In

this study we therefore aimed to investigate sequencing data from a relatively large collection of

sequentially acquired, unselected bloodstream isolates from neonates and children presenting to

hospitals in Oxfordshire, UK, over the past decade.

Methods

Isolate selection

Oxford University Hospitals NHS Foundation Trust is a large healthcare provider in the South East of

England serving a paediatric population of approximately 142,000 across four hospitals (of which

two have emergency and acute general paediatric medicine, and one provides all

neonatal/paediatric critical care and specialist paediatric services for the region). The microbiology

laboratory additionally provides a service to all regional community healthcare providers. All *E. coli*

and *Klebsiella* spp. isolates (deduplicated to one morphotype per 90-day period) from Oct-2008 to

Nov-2018 collected from blood cultures of patients <18 years old on the day of collection were

included in the study. The same selection criteria were applied to other GNB from August-2011 to

September-2018. Prior to 2013 antimicrobial susceptibility testing was performed using disk

diffusion; after this the Phoenix BD system was used with European Committee on Antimicrobial

Susceptibility Testing (EUCAST) breakpoints. Amikacin susceptibility phenotyping was not routinely

performed prior to 2013.

Sequencing procedures

Frozen stocks were sub-cultured onto Columbia blood agar and incubated overnight at 37°C. DNA

extractions were performed using the QuickGene DNA extraction kit (Autogen, MA, USA) as per the

manufacturer's instructions (with an additional mechanical lysis step – FastPrep, MP Biomedicals,

CA, USA; 6m/s for 40 secs, done twice). Sequencing was performed using Illumina HiSeq

2500/3000/4000/MiSeq instruments as described previously[14]. All sequencing data have been

deposited under NCBI accession number PRJNA604975.

Bioinformatics

De novo assembly was performed using Shovill (v1.0.4)[15]. Reads were mapped to sequence type

(ST[16,17]) specific references using Snippy (v4.6.0)[18] (Table S1). For the four *E. coli* STs with the largest

number of isolates (i.e. *E. coli* ST131/95/73/69), we created core genome alignments using Snippy-

core with the --mask auto setting, padded with the reference base at invariant positions; these

whole genome alignments were used as input to Gubbins (v 2.3.4)[19]. Such recombination-corrected

phylogenies were also created for *E.hormaechei* (the most common non-*E. coli/Klebsiella* species

detected in our study) and *S. marcescens* (because there was thought to have been an outbreak in

our neonatal ITU in 2016). We also used genomic distances calculated by Mash[20] (using -k21 -s

100,000 for within-study comparison of isolates and -k21 -s 1000 for comparison of isolates in this

study to our collection of sequences of adult bloodstream infection isolates[21] from the same region

over the same time period due to computational feasibility). Annotation against reference databases

(VFDB/ResFinder) was performed using ABRicate (v2.3.4)[22] with genes called as being present if

there was ≥80% coverage and DNA identity compared to the reference. Sequence types were

predicted using the MLST tool (v2.19)[23]. For *Klebsiella* spp. isolates speciation and virulence gene

detection (appendix) was performed using Kleborate (v2.0.4)[24].

Definitions

We defined isolates as being likely of neonatal origin if they originated from infants i) in their first 30

days of life, or were ii) on the neonatal intensive care unit, or iii) under the care of a neonatologist

on the day the blood culture was taken. For analytical purposes we classified other children as <12

months, 1-4 years, 5-9 years and 10-17 years of age. Early-onset infection was defined as disease

within the first 72 hours of life[25]. We calculated a 'resistance score' using a previously described

method[26] (the sum of the number of resistance gene categories carried out of amoxicillin, co-

trimoxazole, cefotaxime, gentamicin and ciprofloxacin). We further categorised BSIs according to

healthcare exposure prior to onset as follows: nosocomial (>48hours after admission to hospital),

'quasi-nosocomial' (within 30 days of last discharge), 'quasi-community' (31-365 days since last

discharge) and community (>365 days since last discharge)[27]. Genetic relatedness in the form of

single nucleotide polymorphism (SNP) thresholds definitively associated with transmission is variably

defined for the species evaluated; based on recent studies, we considered a threshold of >20 SNVs

between isolates as highly unlikely to be representative of a transmission event[28].

Epidemiology/statistics

Routinely collected healthcare data were acquired via pseudonymised linkage in the Infections in

Oxfordshire Research Database (IORD). IORD has generic Research Ethics Committee, Health

Research Authority and Confidentiality Advisory Group approvals (19/SC/0403, 19/CAG/0144) as a

de-identified electronic research database. Data on suspected infectious focus (only available for *E.*

coli/Klebsiella spp.) were acquired via linked local infection control records which had been

submitted to Public Health England as part of the mandatory surveillance programme. Likely source

was identified by infectious disease/microbiology physicians using best clinical judgement or

designated as unknown where there was significant uncertainty. For each species, we modelled the

number of bloodstream infections (BSIs) per year using negative binomial regression, with the total

number of paediatric admissions in each year used as an offset to account for changes in the

population over time. Only complete years (i.e. excluding 2008 and 2018) were included in this part

of the analysis. Median quantile regression was used to model the relationship between age and

virulence gene carriage/antimicrobial gene "resistance score"; this analysis was performed in STATA

version 15. All other statistical analysis was performed in R v4.0.3.

Results

Microbiology of neonatal and paediatric Gram-negative bloodstream infections in Oxfordshire

Of the 327 GNBSI isolates cultured during the study period from individuals aged <18 years, 149

(46%) were identified as *E. coli* and 69 (21%) as *Klebsiella* spp.; the remaining 109 (33%) belonged to

other species. There was no evidence of a change in the incidence of *E. coli* bloodstream infections

(BSIs) either overall (incidence rate ratio per year [i.e. the relative increase/decrease in incidence per

year] IRRy: 0.96, 95%CI: 0.90-1.03, p=0.30) or in neonates (IRRy: 0.97, 95%CI: 0.86-1.06, p=0.39). This

was also the case for other Gram-negative species both overall (IRRy: 1.07, 95%CI: 0.93-1.24, p=0.33)

and in the neonatal group (IRRy: 0.83, 95%CI: 0.65-1.07, p=0.19). Conversely there was some

evidence of a slight decrease in the overall number of *Klebsiella* spp. BSIs in the same period (overall

IRRy: 0.91, 95%CI 0.83-1.00, p=0.06; neonates IRRy: 0.80, 95%CI: 0.69-0.92, p=0.002).

Neonates had the highest number of GNBSI (124/327 [38%], of which 8 were early-onset) followed

by other infants <1y (66/327 [20%]) (Table 1). There were 62/327 (19%) cases in the 1st-4th years of

life, 28/327 (9%) in the 5th-9th and 47/327 (14%) in the 10th-17th. A higher proportion of isolates came

from males than would be expected from the birth:sex ratio (201/327 [61%], multinomial goodness

of fit p <0.001). BSIs in neonates, children aged 1-4 and 10-17 were predominantly nosocomial or

quasi-nosocomial whereas in those aged 3-12 months and 5-9 years they were predominantly

community or quasi-community onset (Table 1).

167 In our network of hospitals, amoxicillin and gentamicin are used as empirical treatment for neonatal

168 sepsis. In this patient group, 87/119 (73%) isolates were resistant to amoxicillin and 10/122 (8%) to

169 gentamicin (missing data for five and two isolates respectively); 7/118 (6%) isolates (4/56 *E. coli* and

170 3/27 *Klebsiella* spp.) were resistant to both. In older children (>1 month), ceftriaxone is the empirical

171 agent used in our setting and in this population 24/103 (13%) isolates were resistant (missing data

172 for 20 isolates). The proportion of resistant isolates appeared broadly stable over time (figure 1). For

173 gentamicin however, there was some evidence that proportion of susceptible isolates with an MIC

174 >1mg/L (IRR$_y$ 1.86, 95%CI 1.33-2.58) increased compared to those with an MIC <=1mg/L (IRR$_y$ 1.13,

175 95%CI 1.04-1.22) $p_{heterogeneity}$=0.002 (EUCAST gentamicin breakpoint for resistance >2mg/L). There

176 was no evidence of substantial differences in phenotypic profiles between treating specialties

177 (Figure S1). Similarly, the proportion of resistant isolates was similar for nosocomial vs. community-

178 onset cases for all agents except amoxicillin where nosocomial isolates were proportionally more

179 resistant (99/118 (84%) vs 115/174 (66%), table S1), reflecting the higher burden of non-*E. coli* BSIs

180 in this patient group (77/126 (61%) vs 101/201 (50%).

182 Data on likely primary infective focus was only available for 78 isolates (66 *E. coli*/12 *Klebsiella* spp.),

183 of these 18 (23%) were of gastrointestinal origin, 8 (10%) from invasive lines, 20 (26%) from the

184 urinary tract, 2 (3%) from the chest and 30 (38%) from unclear/other sources. Seventeen children

185 (six neonates) had infections with >1 species and five (two neonates) had polyclonal infections (>1 ST

186 of the same species).

188 **Molecular epidemiology of *Escherichia coli* causing BSI, including AMR and virulence gene burden**

189 Of the 146 *E. coli* isolates cultured, 133 (87%) were successfully sequenced (Figure 2). The four

190 dominant *E. coli* STs (ST131 n=16, ST95 n=16, ST73 n=20 and ST 69 n=15) were the same as those in

adults[21]. There was no evidence that the population structure observed differed from that in the

adult population in Oxfordshire (which is also the same as that observed globally[21]; multinomial

goodness of fit: p=0.44). The most prevalent O-antigen types were O6 (n=21), O1 (n=14), O2 (n=12),

O16 (n=10) and O25 (n=8). The proportion of isolates with an O-antigen included in the ExPEC-4V

vaccine[29,30] (which has been evaluated in a phase-II study in adults), was similar when comparing all

children (55/133, 41%) and neonates (25/53, 47%) to that seen in the overall population in our

previous study[31] (1499/3278 (46%); chi-squared: p=0.4 for both).

Carriage of genes conferring resistance to ampicillin was common (65/133, 49%), with bla_{TEM-1B}

(39/67, 58%) being the most prevalent allele. Eight isolates carried a gentamicin resistance gene (5

aac(3)-IIa [3 in ST131, 1 each in STs 73 and 23] and 3 *aac(3)-IId* [1 each in STs95 and 69]) and 20/133

(15%) carried a gene conferring resistance to ceftriaxone or cefotaxime (mostly ESBL genes, namely

$bla_{CTX-M-15}$ [n=9], $bla_{CTX-M-14b}$ [n=3] and $bla_{SHV-102}$ [n=5]); Figure 3). Whilst ST131 was the dominant ESBL-

gene-carrying ST (7/16, 44%), other STs carrying these genes included ST69 (2/15), ST73 (4/20),

ST2141 (3/3), ST12 (2/7) and STs 23 and 38 (1 each). Quantile regression revealed some association

between increasing age and increased resistance score (change in median per year, CMy=0.12, 95%

CI 0.04-0.19, p =0.002). Conversely there was some evidence that virulence gene carriage was higher

in younger children (CMy = -0.53 95%CI -1.03 - -0.033, p=0.04 Figure S2).

Molecular epidemiology of *Klebsiella* spp. causing BSI, including AMR and virulence gene burden

Of the 69 *Klebsiella* spp. isolates cultured, 60 (87%) were successfully sequenced. The predominant

Klebsiella spp. in both neonates and older infants/children was *Klebsiella pneumoniae* (n=28/60

[47%]), though a diverse selection of related species were also occasionally isolated (*K. oxytoca*:

n=12 [20%], *K. michiganensis*: n=8 (13%), *K. aerogenes*: 5 (8%), *K. grimontii*: n=3 (5%), *K.*

ornithinolytica: n=2 (3%) and *K. variicola*: n=2 (3%)). As we have previously observed in adults and in

contrast to the more clonal population seen in *E. coli*, STs causing *Klebsiella* spp. BSI were diverse

(n=32 STs in total). There were 11 isolates to which no ST could be assigned. We recently observed

that four O-antigens (O2v2, O1v1, O3b and O1v2) were found in 75% isolates from all *K. pneumoniae*

BSIs in Oxfordshire over a ten-year period; amongst paediatric BSIs this figure was 61% (17/28;

Fisher's exact test: p=0.15).

Half of *Klebsiella* spp. isolates (30/60) carried the yersiniabactin virulence factor (*ybt*); these were

mostly non-*K. pneumoniae* (12/12 *K. oxytoca*, 7/8 *K. michiganensis*, 2/2 *K. ornitholytica* and 3/3 *K.*

grimontii). One *K. aerogenes* isolate additionally carried the genotoxin colibactin (*clb*). There was no

difference in the proportion of E. coli/Klebsiella spp. isolates carrying a gene conferring ceftriaxone

resistance (19/137, 14% vs 9/66, 14%, p=0.99). Only 4/60 (7%) isolates carried a gentamicin

resistance gene (four *aac(3)-IIa* and one *aac(3)-Ia*, similar to *E. coli* (8/133, 6%); Fisher's exact test:

p=0.90).

Other Gram-negative species

Of the 104 non-*E. coli/Klebsiella* spp. ("other") GNB cultured in this study, 77 (74%) were successfully

sequenced. The predominant species in both neonates and older children was *E. hormaechei*

(overall: 34/75, [44%]; neonatal: 14/25 [56%]). This was also the only other species carrying ESBL-

producing genes ($bla_{CTX-M-15}$ in four isolates, Figure 3); these isolates also carried the bla_{TEM-1B} beta-

lactamase as well as *aac(3)-IIa* conferring gentamicin resistance. Two isolates carrying class-D beta-

lactamases predicted to confer carbapenem resistance were identified (bla_{OXA-23} in *Acinetobacter*

baumannii, $bla_{OXA-427}$ in *Aeromonas caviae*).

Genomic relatedness of isolates

Analysis of recombination-corrected phylogenies for the major *E. coli* STs (131/95/69) demonstrated no clear evidence of direct or temporally related indirect transmission between patients (with the closest genomic distance between patients = 32/87/28 single nucleotide variants [SNV] for ST131/95/69 respectively). There was a cluster of three near-identical ST73 isolates from two patients (3/6 SNPs apart), however the isolation date was ~2 years apart and these patients had never been admitted to hospital at the same time. There was a cluster of three multidrug-resistant *E. hormaechei* isolates separated by a maximum of 37 SNPs. All three patients had been admitted in the same year but not at the same time and to different wards. Other *E. hormaechei* isolates were genomically diverse (Figure 4). Three *S. marcescens* from the neonatal ICU in 20116 were grouped together in the phylogeny (Figure S3) however the relatively large distances between them (31/81/85 SNPs), made recent transmission unlikely.

There was no difference in the distributions of genomic distances (reflected here by Mash distances) between isolates from patients admitted i) in the same year, ii) to the same ward in the same year, or iii) to the same ward with overlapping admission dates and iv) overall (i.e. all admissions to any ward at any time point) (Kruskal-Wallis rank sum test p=0.30, Figure S4). Finally, when considering *E. coli* and *Klebsiella* isolates in this study, there was no difference between the Mash distances to the nearest paediatric genomic neighbour (median: 0.00093 [IQR: 0.00036-0.0023]) compared to the nearest adult neighbour (median: 0.0011 [IQR: 0.00041-0.0024], Wilcoxon rank sum p=0.33. Figure S5).

Discussion

E. coli was the main causative agent of paediatric and neonatal Gram-negative bloodstream infection

in our study over a ten year period. The population structure of *E. coli* isolates causing invasive

infection in children mirrors that seen in our centre and globally for adults. We found no evidence of

significant nosocomial transmission suggesting that in our setting invasive isolates are acquired from

the environment or as a result of colonisation from parents/other close contacts. Our findings

suggest O-antigen targeted vaccines (currently in phase II/III trials in adults) might have the potential

to reduce the incidence of invasive neonatal and paediatric *E. coli* infections, in the former

potentially by immunisation of pregnant women. Most isolates remained susceptible to at least one

first-line antibiotic justifying continuation of current empirical treatment guidelines which should

include an aminoglycoside in neonates[25]. There was however some evidence of increasing (sub-

breakpoint) gentamicin MIC which warrants ongoing surveillance, and 1 in 20 GNBSIs were caused

by isolates resistant to the ampicillin+gentamicin combination.

The incidence of these infections has remained stable over the past decade in children, in contrast to

the increase observed in adults. The substantial burden of disease due to paediatric GNBSI occurs in

neonates. The absence of evidence of an increasing burden of AMR-associated disease and

demonstrable outbreaks likely points to good infection control practice and antimicrobial

stewardship, and in our setting we were able to replicate results from a previous study[26] suggesting

greater carriage of virulence genes in *E. coli* isolates from younger children and neonates but higher

resistance scores in older children. Continued epidemiological surveillance with targeted whole

genome sequencing to identify strain and/or plasmid outbreaks may help to inform early infection

control interventions and would seem particularly justified in these age groups given the high

associated morbidity and mortality. In addition we would encourage consideration of clinical trials of

existing O-antigen targeted vaccines for prevention of neonatal sepsis.

Our data suggest that rates of infection with non-*E. coli/Klebsiella* spp. (in particular *E. hormachei)*

are higher in the neonatal and paediatric settings than in adults. These results highlight the

importance of this pathogen as a potential causative agent of neonatal and paediatric sepsis as well

as its potential to cause multidrug-resistant outbreaks in this setting. Several small clusters of *E.*

hormaechei (part of the *E. cloacae* complex) bloodstream infection in neonates have been described

in the literature, with enteral feeding and milk formulations as well as poor general infection control

procedures thought to be implicated[32–34].

Our data highlights the value of whole genome sequencing for the investigation of potential

outbreaks on neonatal units. WGS analysis of three isolates from a suspected (on the basis of

epidemiology and pulsed-field gel electrophoresis) *S. marcescens* outbreak suggested recent

transmission was actually highly unlikely. Had this analysis been performed in real-time it may have

reassured clinicians and saved time and resource. Apart from a small cluster of three patients with *E.*

hormaechei infections where acquisition from a common source was possible based on genomic and

epidemiological analysis (though the patients were never admitted to the same ward), there was

relatively high diversity amongst isolates effectively ruling out transmission/point-source acquisition

resulting in BSI. However, unwell neonates are often transferred across a geographic region for

specialist care and so it is essential that active surveillance mechanisms (collecting and analysing

real-time microbiological data) are implemented across networks in order to inform infection

prevention measures appropriately.

Notably, whilst we found a lack of clear evidence of transmission between patients in this study, BSIs

are likely to represent an extremely insensitive marker of transmission events, as most transmission

with these organisms would be expected to lead to colonisation and not necessarily invasive

infection. Furthermore whilst the short-read sequencing used in this study allows us to confidently

exclude outbreaks of strains, we cannot address the question of potential transmission of AMR

genes and virulence factors on plasmids. Additional limitations include the fact that we were not

able to sequence all cultured isolates, the relatively sparse availability of data on source attribution

and the single region nature of the study. We did not sample other reservoirs potentially

contributing to transmission, including the unit environment.

In summary, our study highlights a relative success story of a flat overall incidence trend and stable

numbers of AMR-carrying GNBSI isolates in children, contrasting with what has been seen in adult

populations in the same setting[21]. Pertinently our data supports the ongoing use of an

aminoglycoside as part of empirical treatment guidelines in neonatal sepsis. The disproportionate

impact of GNBSI on neonates and young infants should encourage active microbiological surveillance

across neonatal networks and strategies to prevent disease through vaccine trials in pregnant

women.

Figure legends

Figure 1 – Change in minimum inhibitory concentrations (MIC) of isolates over time.

Figure 2 - Species (and sequence type, ST, where shown) for sequenced isolate over time. Each

point represents the isolation date of a sequenced isolate. The grey shaded area represents the fact

that sequencing of non-*E. coli/Klebsiella* spp. isolates did not begin prior to 2012.

Figure 3 – Carriage of antimicrobial resistance genes by isolates sequenced in the study. The tree

was created using mashtree and gene presence is shown in red. The black/green/maroon/orange

bars at the top represent carriage of genes producing enzymes with activity against

aminoglycosides/amoxicillin/cefotaxime/ceftriaxone respectively.

Figure 4 – Recombination corrected phylogeny of *Enterobacter hormaechei* isolates sequenced in

this study. Tree tip colours show the year of isolates, red bars denote presence/absence of

antimicrobial resistance genes. The scale of the tree is shown in SNPs.

Table legend

Table 1 – microbiological and patient characteristics of patients with Gram-negative bloodstream

infections in Oxfordshire stratified by age of onset. P values represent Fisher exact tests for

categorical and Kruskal-Wallis tests for continuous variables.

Ethics Statement

The Infections in Oxfordshire Research Database (IORD; https://oxfordbrc.nihr.ac.uk/research-

themes-overview/antimicrobial-resistance-and-modernising-microbiology/infections-in-oxfordshire-

research-database-iord/) has generic Research Ethics Committee, Health Research Authority and

Confidentiality Advisory Group approvals (19/SC/0403, 19/CAG/0144) which facilitate the pseudo-

anonymised linkage of routinely collected NHS electronic healthcare record data from the Oxford

University Hospitals NHS Foundation Trust Clinical Systems Data Warehouse and research data (e.g.

sequencing data) from the Antimicrobial Resistance and Modernising Microbiology Theme of the

Oxford NIHR Biomedical Research Centre, Oxford. IORD links records by a specific, random, number

ensuring that no patient-identifiable information is shared with researchers using this resource. We

sequenced bacterial isolates from bloodstream infections that are routinely stored by the John

Radcliffe Hospital Microbiology laboratory. In the UK, bacterial isolates (such as those sequenced in

this study) routinely cultured from human clinical samples do not require ethical approval for

analysis under the provisions of the Human Tissue Act as they do not contain any material

considered to be human tissue.

References

1.   Malande OO, Nuttall J, Pillay V, Bamford C, Eley B. A ten-year review of ESBL and non-ESBL

Escherichia coli bloodstream infections among children at a tertiary referral hospital in South

Africa. *PLoS One*. 2019;14(9):e0222675.

2.   Powell EC, Mahajan PV, Roosevelt G, et al. Epidemiology of Bacteremia in Febrile Infants Aged

60 Days and Younger. *Ann Emerg Med*. 2018;71(2):211-216.

3.   Shakur SM, Whitehall J, Mudgil P. Pediatric bloodstream infections in metropolitan Australia.

World J Pediatr. 2019;15(2):161-167.

4.   Agyeman PKA, Schlapbach LJ, Giannoni E, et al. Epidemiology of blood culture-proven bacterial

sepsis in children in Switzerland: a population-based cohort study. *Lancet Child Adolesc Health*.

2017;1(2):124-133.

5.   Stoll BJ, Puopolo KM, Hansen NI, et al. Early-Onset Neonatal Sepsis 2015 to 2017, the Rise of

Escherichia coli, and the Need for Novel Prevention Strategies. *JAMA Pediatr*.

2020;174(7):e200593.

6.   *Annual Publication of Epidemiological Commentary*. Public Health England; 2020.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat

a/file/940716/Annual_epidemiology_commentary_April_2019_March_2020.pdf

7.   Flannery DD, Akinboyo IC, Mukhopadhyay S, et al. Antibiotic Susceptibility of Escherichia coli

Among Infants Admitted to Neonatal Intensive Care Units Across the US From 2009 to 2017.

JAMA Pediatr. 2021;175(2):168-175.

8.   Sands K, Carvalho MJ, Portal E, et al. Characterization of antimicrobial-resistant Gram-negative

bacteria that cause neonatal sepsis in seven low- and middle-income countries. *Nat Microbiol*.

2021;6(4):512-523.

9.   Gkentzi D, Kortsalioudaki C, Cailes BC, et al. Epidemiology of infections and antimicrobial use in

Greek Neonatal Units. *Arch Dis Child Fetal Neonatal Ed*. 2019;104(3):F293-F297.

10. Kallonen T, Brodrick HJ, Harris SR, et al. Systematic longitudinal survey of invasive Escherichia

coli in England demonstrates a stable population structure only transiently disturbed by the

emergence of ST131. *Genome Res*. Published online July 18, 2017. doi:10.1101/gr.216606.116

11. Ellington MJ, Heinz E, Wailan AM, et al. Contrasting patterns of longitudinal population

dynamics and antimicrobial resistance mechanisms in two priority bacterial pathogens over 7

years in a single center. *Genome Biol*. 2019;20(1):184.

12. Giuffrè M, Cipolla D, Bonura C, et al. Outbreak of colonizations by extended-spectrum β-

lactamase-producing Escherichia coli sequence type 131 in a neonatal intensive care unit, Italy.

Antimicrob Resist Infect Control. 2013;2(1):8.

13. Stoesser N, Giess A, Batty EM, et al. Genome sequencing of an extended series of NDM-

producing Klebsiella pneumoniae isolates from neonatal infections in a Nepali hospital

characterizes the extent of community- versus hospital-associated transmission in an endemic

setting. *Antimicrob Agents Chemother*. 2014;58(12):7347-7357.

14. De Maio N, Shaw LP, Hubbard A, et al. Comparison of long-read sequencing technologies in the

hybrid assembly of complex bacterial genomes. *Microb Genom*. 2019;5(9).

doi:10.1099/mgen.0.000294

15. Seemann T. Shovill. Accessed May 18, 2020. https://github.com/tseemann/shovill

16. Wirth T, Falush D, Lan R, et al. Sex and virulence in Escherichia coli: an evolutionary perspective.

405   *Mol Microbiol*. 2006;60(5):1136-1151.

406   17. Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisse S. Multilocus sequence typing of Klebsiella

407   pneumoniae nosocomial isolates. *J Clin Microbiol*. 2005;43(8):4178-4182.

408   18. Seemann T. *Snippy*. Github; 2015. Accessed September 12, 2017.

409   https://github.com/tseemann/snippy

410   19. Croucher NJ, Page AJ, Connor TR, et al. Rapid phylogenetic analysis of large samples of

411   recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res*.

412   2015;43(3):e15.

413   20. Ondov BD, Treangen TJ, Melsted P, et al. Mash: fast genome and metagenome distance

414   estimation using MinHash. *Genome Biol*. 2016;17(1):132.

415   21. Lipworth S, Vihta K-D, Chau K, et al. Molecular epidemiology of Escherichia coli and Klebsiella

416   species bloodstream infections in Oxfordshire (UK) 2008-2018. *medRxiv*. Published online 2021.

417   22. Seemann T. *Abricate*. Github Accessed July 5, 2019. https://github.com/tseemann/abricate

418   23. Seemann T. *Mlst*. Github Accessed July 12, 2019. https://github.com/tseemann/mlst

419   24. Holt K. Kleborate. Accessed May 22, 2020. https://github.com/katholt/Kleborate

420   25. *Neonatal Infection: Antibiotics for Prevention and Treatment*. National Institute for Clinical

421   Excellence Accessed May 4, 2021. https://www.nice.org.uk/guidance/ng195

422   26. Burdet C, Clermont O, Bonacorsi S, et al. Escherichia coli bacteremia in children: age and portal

423   of entry are the main predictors of severity. *Pediatr Infect Dis J*. 2014;33(8):872-879.

27. Vihta K-D, Stoesser N, Llewelyn MJ, et al. Trends over time in Escherichia coli bloodstream

infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016:

a study of electronic health records. *Lancet Infect Dis*. 2018;18(10):1138-1149.

28. Wyres KL, Hawkey J, Mirčeta M, et al. Genomic surveillance of antimicrobial resistant bacterial

colonisation and infection in intensive care patients. *BMC Infect Dis*. 2021;21(1):683.

29. Frenck RW Jr, Ervin J, Chu L, et al. Safety and immunogenicity of a vaccine for extra-intestinal

pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. *Lancet Infect Dis*.

2019;19(6):631-640.

30. Huttner A, Gambillara V. The development and early clinical testing of the ExPEC4V conjugate

vaccine against uropathogenic Escherichia coli. *Clin Microbiol Infect*. 2018;24(10):1046-1050.

31. Lipworth S, Vihta K-D, Chau KK, et al. Ten years of population-level genomic Escherichia coli and

Klebsiella pneumoniae serotype surveillance informs vaccine development for invasive

infections. *Clin Infect Dis*. Published online January 7, 2021. doi:10.1093/cid/ciab006

32. Giammanco GM, Aleo A, Guida I, Mammina C. Molecular epidemiological survey of Citrobacter

freundii misidentified as Cronobacter spp. (Enterobacter sakazakii) and Enterobacter

hormaechei isolated from powdered infant milk formula. *Foodborne Pathog Dis*. 2011;8(4):517-

525.

33. El-Zamkan MA, Mohamed HMA. Molecular detection ofEnterobacterspp. and other related

species in powdered milk infant formula and milk powder. *J Food Saf*. 2018;38(6):e12538.

34. da Silva CLP, Miranda LEV, Moreira BM, et al. Enterobacter hormaechei bloodstream infection

at three neonatal intensive care units in Brazil. *Pediatr Infect Dis J*. 2002;21(2):175-177.

		Neonatal Early Onset	Neonatal Late Onset	<12 months	1-4 years	5-9 years	10-17 years	p
Species (%)	*Acinetobacter* spp.	1 (12.5)	3 (2.6)	6 (9.1)	9 (14.5)	4 (14.3)	4 (8.5)	<0.001
	E. coli	6 (75.0)	51 (44.0)	42 (63.6)	17 (27.4)	6 (21.4)	27 (57.4)	
	Enterobacter spp.	1 (12.5)	24 (20.7)	8 (12.1)	13 (21.0)	5 (17.9)	4 (8.5)	
	Citrobacter spp.		2 (1.7)		2 (3.2)	3 (10.7)	1 (2.1)	
	Klebsiella spp.		28 (24.1)	10 (15.2)	16 (25.8)	6 (21.4)	9 (19.1)	
	Serratia spp.		8 (6.9)				1 (2.1)	
	Aeromonas spp.				3 (4.8)	1 (3.6)		
	Proteus spp.				2 (3.2)			
	Pantoea spp.					3 (10.7)	1 (2.1)	
Age	Median (IQR)	0.0 (0.0 to 1.2)	20.0 (11.8 to 49.2)	91.0 (57.5 to 177.5)	689.0 (512.2 to 969.8)	1893.0 (1770.0 to 2346.2)	5391.0 (3992.5 to 6168.5)	<0.001
Sex (%)	Female	4 (50.0)	38 (32.8)	28 (42.4)	28 (45.2)	9 (32.1)	19 (40.4)	0.51
	Male	4 (50.0)	78 (67.2)	38 (57.6)	34 (54.8)	19 (67.9)	28 (59.6)	

		Neonatal Early Onset	Neonatal Late Onset	<12 months	1-4 years	5-9 years	10-17 years	p
Specimen (%) Category	Nosocomial	0 (0.0)	86 (74.1)	7 (10.6)	18 (29.0)	0 (0.0)	15 (31.9)	<0.001
	Healthcare associated 0-30d	2 (25.0)	15 (12.9)	8 (12.1)	21 (33.9)	13 (46.4)	16 (34.0)	
	Healthcare associated 31-365d	0 (0.0)	3 (2.6)	29 (43.9)	11 (17.7)	4 (14.3)	5 (10.6)	
	Community	6 (75.0)	12 (10.3)	22 (33.3)	12 (19.4)	11 (39.3)	11 (23.4)	
Admission Length	Median (IQR)	14.2 (9.9 to 27.5)	51.7 (20.8 to 129.7)	4.1 (2.5 to 7.9)	8.8 (2.5 to 30.6)	3.1 (2.1 to 7.8)	5.5 (2.9 to 28.0)	<0.001
Death Within 30 Days (%)	No	6 (75.0)	86 (76.1)	44 (67.7)	52 (83.9)	21 (75.0)	39 (83.0)	0.30
	Yes	2 (25.0)	27 (23.9)	21 (32.3)	10 (16.1)	7 (25.0)	8 (17.0)	
CRP	Median (IQR)	8.2 (0.6 to 37.9)	64.1 (16.1 to 150.3)	99.2 (45.5 to 125.0)	50.1 (10.1 to 122.2)	16.7 (5.0 to 56.8)	59.2 (13.9 to 118.4)	0.08
Creatinine	Median (IQR)	61.0 (55.0 to 78.0)	37.0 (23.0 to 60.8)	24.0 (18.0 to 28.0)	22.0 (16.0 to 32.0)	36.0 (28.0 to 41.0)	55.5 (45.0 to 66.5)	<0.001

		Neonatal Early Onset	Neonatal Late Onset	<12 months	1-4 years	5-9 years	10-17 years	p
Neutrophils	Median (IQR)	2.9 (1.9 to 10.1)	5.9 (3.1 to 9.8)	9.3 (5.4 to 15.0)	5.5 (2.7 to 11.3)	3.5 (1.9 to 7.2)	4.6 (0.1 to 8.4)	0.004
Amoxicillin	S	5 (71.4)	27 (24.1)	25 (42.4)	11 (22.0)	5 (20.8)	5 (12.5)	0.002
(missing=35)	R	2 (28.6)	85 (75.9)	34 (57.6)	39 (78.0)	19 (79.2)	35 (87.5)	
Ceftriaxone	S	6 (85.7)	96 (85.0)	57 (93.4)	43 (81.1)	23 (85.2)	36 (85.7)	0.46
(missing=24)	R	1 (14.3)	17 (15.0)	4 (6.6)	10 (18.9)	4 (14.8)	6 (14.3)	
Meropenem	S	8 (100.0)	115 (100.0)	62 (100.0)	61 (100.0)	28 (100.0)	43 (97.7)	0.26
(missing=9)	R	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.3)	
Ciprofloxacin	S	7 (87.5)	110 (95.7)	62 (100.0)	55 (91.7)	27 (96.4)	39 (88.6)	0.05
(missing=10)	R	1 (12.5)	5 (4.3)	0 (0.0)	5 (8.3)	1 (3.6)	5 (11.4)	
Amikacin	S	3 (100.0)	47 (90.4)	15 (100.0)	21 (87.5)	17 (100.0)	21 (91.3)	0.63
(missing=193)	R	0 (0.0)	5 (9.6)	0 (0.0)	3 (12.5)	0 (0.0)	2 (8.7)	
Gentamicin	S	7 (87.5)	105 (92.1)	60 (96.8)	53 (86.9)	25 (92.6)	38 (86.4)	0.27

		Neonatal Early Onset	Neonatal Late Onset	<12 months	1-4 years	5-9 years	10-17 years	p
(missing=11)	R	1 (12.5)	9 (7.9)	2 (3.2)	8 (13.1)	2 (7.4)	6 (13.6)	
Piperacillin-Tazobactam	S	8 (100.0)	105 (92.1)	56 (93.3)	48 (85.7)	23 (88.5)	37 (86.0)	0.57
(missing=20)	R		9 (7.9)	4 (6.7)	8 (14.3)	3 (11.5)	6 (14.0)	
Fosfomycin	S	1 (100.0)	45 (93.8)	10 (90.9)	14 (87.5)	11 (84.6)	18 (94.7)	0.72
(missing=219)	R		3 (6.2)	1 (9.1)	2 (12.5)	2 (15.4)	1 (5.3)	